Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study

Lahbabi, M.; Alaoui, Samia; Rhazi, Karima El; Abkari, Mohammed El; Nejjari, Chakib; Amarti, Afaf; Bennani, Bahia; Mahmoud, Mustapha; Ibrahimi, A.; Benajah, Dafr Allah

doi:10.1016/j.clinre.2012.10.002

Cited by 24 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are almost the same as our study. In another study, Lahbabi et al showed that sequential therapy had 94.2% and 96% successful eradication rate using intention-to-treat and per-protocol analysis respectively (20). In this study, like our study, it was shown that the sequential therapy method in comparison with other methods had better efficacy.…”

Section: Discussionsupporting

confidence: 70%

“…In the study of Nasa et al, unlike our study, the prevalence of side effects was not significantly different between the two groups, and was 23.5% and 14.6% in the sequential therapy group and the standard triple therapy group, respectively (19). In the study of Lahbabi et al similar to our study, the prevalence of drug side effects in the sequential therapy group was 6.9% which was significantly lower than the standard triple therapy group (20). The study of Vaira et al mentioned the incidence of drug side effects by 17% in each group, which was not statistically significant and is contradictory with our study results (21).…”

Section: Discussioncontrasting

confidence: 51%

See 1 more Smart Citation

Sequential Therapy versus Standard Triple Therapy for Helicobacter Pylori Eradication in Iran: a double-blind, randomized, placebo-controlled trial

Moosavi¹,

Mahboobi²,

Dadvand³

2019

Electron. physician

View full text Add to dashboard Cite

Background and aim: Currently, different regimens are used for Helicobacter pylori eradication. The aim of this study is to compare the efficacy and safety of sequential and standard triple therapy for Helicobacter pylori eradication in Bandar Abbas in 2018. Methods: This randomized controlled trial was done on 150 patients in Bandar Abbas in 2018. Patients were randomly assigned into two groups either to receive standard triple therapy or sequential therapy for Helicobacter pylori eradication. Patients were followed for helicobacter eradication, minor and major side effects and drug intolerance. Data were analyzed using SPSS 23.0 software. Results: Two groups were similar in baseline characteristics. Helicobacter pylori eradication was reported in 70 (90.9 %) in the sequential and 54 (74 %) in the standard triple therapy group (p=0.006). Minor side effects were reported in 20 (26 %) in the sequential and 36 (49.3 %) in the standard triple therapy (p=0.003). Major side effects (p=0.142) and drug intolerance (p=0.480) were similar in both groups. Conclusion: Sequential therapy is more effective and has lower rate of minor complications in eradication of Helicobacter pylori. Trial registration: The protocol of study was registered at the Iranian Registry of Clinical Trials (IRCT) with ID number of IRCT20180131038581N2.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussioncontrasting

confidence: 51%

Sequential Therapy versus Standard Triple Therapy for Helicobacter Pylori Eradication in Iran: a double-blind, randomized, placebo-controlled trial

Moosavi¹,

Mahboobi²,

Dadvand³

2019

Electron. physician

View full text Add to dashboard Cite

show abstract

“…Two recent clinical trials conducted in Morocco suggested a high rate of clarithromycin resistance. The first, conducted in 2009, showed eradication rates lower than 80% for clarithromycin-based triple therapy (ITT 78.2, PP 79.6) and the second, conducted in 2012, showed a decline in the eradication rates achieved by this regimen (ITT 65.9, PP 71), thereby suggesting an increase of the resistance rate to clarithromycin [5,6].…”

mentioning

confidence: 99%

High‐level primary clarithromycin resistance of Helicobacter pylori in Morocco: a prospective multicenter molecular study

Bouilhat¹,

Burucoa

Bourazza

et al. 2015

Helicobacter

View full text Add to dashboard Cite

“…In Morocco, two randomized studies were performed comparing sequential to standard therapy. In both, sequential therapy performed impressively against standard triple, with ITT eradication rates of 65.9% in the standard triple therapy group and 82.8 in the sequential therapy group in one, and 94.2% for sequential and 70% for metronidazole‐based triple therapy and 78% for clarithromycin‐based triple in the other . Another two randomized, prospective studies carried out in India also showed significantly better eradication rates for sequential therapy .…”

Section: Non‐bismuth Quadruple Sequential and Concomitant Therapymentioning

confidence: 92%

Treatment of Helicobacter pylori Infection 2014

et al. 2014

View full text Add to dashboard Cite

This review summarizes important studies regarding H.pylori therapy published from April 2013 to April 2014. The main themes that emerge are assessing the efficacy of standard triple therapy, as well as exploring new first-line treatments, predominantly optimized triple therapies and non-bismuth quadruple schemes. Regarding newer non-bismuth quadruple regimens, the compliance and tolerance seem to be similar for sequential and concomitant regimens. Notably, no study yet has demonstrated a clear statistical superiority for either, and a systematic review and meta-analysis may be warranted. Other studies examined the role of levofloxacin and bismuth based therapies in H. pylori eradication. The efficacy of bismuth as a second-line after sequential therapy was particularly noteworthy. Levofloxacin-based therapies also appear to be useful and versatile as part of different antibiotic combinations and in first-, second-, and third-line therapies. The emerging problem of quinolone resistance remains a worry. Individualized therapy, based on factors such as antimicrobial information, resistance data, and CYP2C19 metabolism, may well be the most notable future trend to emerge this year.

show abstract

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study

Cited by 24 publications

References 35 publications

Sequential Therapy versus Standard Triple Therapy for Helicobacter Pylori Eradication in Iran: a double-blind, randomized, placebo-controlled trial

Sequential Therapy versus Standard Triple Therapy for Helicobacter Pylori Eradication in Iran: a double-blind, randomized, placebo-controlled trial

High‐level primary clarithromycin resistance of Helicobacter pylori in Morocco: a prospective multicenter molecular study

Treatment of Helicobacter pylori Infection 2014

Contact Info

Product

Resources

About